Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide

被引：117
|
作者：
Glicklich, D [1 ]
Acharya, A [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Renal, Bronx, NY 10467 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 1998年 / 32卷 / 02期
关键词：
lupus nephritis; cyclophosphamide; mycophenolate mofetil;
D O I：
10.1053/ajkd.1998.v32.pm9708620
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
intravenous (IV) cyclophosphamide has been the treatment of choice for diffuse proliferative glomerulonephritis (DPGN) in patients with systemic lupus erythematosus (SLE), However, there is little guidance in the medical literature about what to do when this therapy fails. Mycophenolate mofetil (MMF), a new immunosuppressive agent, has been used successfully in patients with solid organ transplants and rheumatoid arthritis. We report two patients with diffuse proliferative glomerulonephritis who responded favorably to MMF therapy after IV cyclophosphamide failed. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码：318 / 322
页数：5
相关论文
共 50 条
  • [1] Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis
    Killen, JP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07): : 764 - 765
  • [2] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ginzler, EM
    Dooley, MA
    Aranow, C
    Kim, MY
    Buyon, J
    Merrill, JT
    Petri, M
    Gilkeson, GS
    Wallace, DJ
    Weisman, MH
    Appel, GB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21): : 2219 - 2228
  • [3] Mycophenolate mofetil for lupus nephritis refractory to cyclophosphamide
    Baños, I
    Yebra, M
    Fernández, J
    Cajal, YSR
    [J]. MEDICINA CLINICA, 2003, 121 (04): : 158 - 158
  • [4] Mycophenolate mofetil in lupus nephritis refractary to intravenous cyclophosphamide
    Daza, Leonel
    Perez, Salvador
    Velasco, Ulises
    Hernandez, Martha
    [J]. REUMATOLOGIA CLINICA, 2006, 2 (05): : 247 - 250
  • [5] Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis - Reply
    Ginzler, EM
    Dooley, MA
    Kim, MY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07): : 765 - 765
  • [6] Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
    Radhakrishnan, Jai
    Moutzouris, Dimitrios-Anestis
    Ginzler, Ellen M.
    Solomons, Neil
    Siempos, Ilias I.
    Appel, Gerald B.
    [J]. KIDNEY INTERNATIONAL, 2010, 77 (02) : 152 - 160
  • [7] Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine
    Fu, YF
    Liu, GL
    [J]. CLINICAL NEPHROLOGY, 2001, 55 (04) : 318 - 321
  • [8] Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis.
    Park, Dong-Jin
    Lee, Kyung-Eun
    Kim, Tae-Jong
    Park, Yong-Wook
    Lee, Shin-Seok
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S952 - S953
  • [9] Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
    Contreras, G
    Tozman, E
    Nahar, N
    Metz, D
    [J]. LUPUS, 2005, 14 : S33 - S38
  • [10] Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide
    Christian Burchardi
    Detlef Schlöndorff
    [J]. Nature Clinical Practice Nephrology, 2006, 2 : 314 - 315
12345